A fermentation bacterium with a ninety-year commercial history and a broad, shallow evidence base tied to the companies selling it. The clearest findings are fewer common respiratory and stomach infections and less day-to-day burden from hay-fever symptoms. Almost every effect belongs to a named strain, not the species, so a product without that code carries none of the evidence. (Full Review)
| Marker | Target | Why |
|---|---|---|
| High-sensitivity C-reactive protein (hs-CRP) | < 0.5 mg/L | General inflammation; fell in the older-adult strength trial |
| Interleukin-6 | < 1.5 pg/mL | The specific inflammatory signal that fell with this species |
| Low-density lipoprotein cholesterol | < 80 mg/dL | The fraction one strain trial moved, and the main driver of arterial plaque |
| Remnant cholesterol | < 20 mg/dL | The exact fraction that fell in the metabolic syndrome trial |
| Triglycerides | < 80 mg/dL | Moved alongside remnant cholesterol in compliant participants |
| Glycated haemoglobin (HbA1c) | 4.8 – 5.2 % | Detects metabolic drift from a sugar-containing fermented-milk carrier |
| Absolute neutrophil count | > 1.5 × 10⁹/L | The safety gate: neutropenia is the documented setting for invasive infection |
Cadence: Repeat lipids and inflammatory markers at 12 weeks, then at 6 to 12 month intervals if the course continues; symptom tracking daily for the first two weeks and weekly thereafter.